(Q46406579)

21 December 2017

title

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients (English)

1 reference

21 December 2017

1 reference

E Dias-Neto

7

0 references

Guilherme Suarez-Kurtz

object named as

G Suarez-Kurtz

8

0 references

author name string

J A Perini

1

1 reference

21 December 2017

C J Struchiner

2

1 reference

21 December 2017

E Silva-Assunção

3

1 reference

21 December 2017

I S C Santana

4

1 reference

21 December 2017

F Rangel

5

1 reference

21 December 2017

E B Ojopi

6

1 reference

21 December 2017

language of work or name

English

0 references

publication date

27 August 2008

1 reference

21 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

21 December 2017

volume

84

1 reference

21 December 2017

issue

6

1 reference

21 December 2017

page(s)

722-728

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1038/clpt.2008.166

exact match

0 references

cites work

Hemorrhagic complications of anticoagulant treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Factors influencing warfarin dose requirements in African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Pharmacogenomics in admixed populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Pharmacogenomics in the Americas: the impact of genetic admixture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Evaluation of genetic factors for warfarin dose prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

APOE genotype makes a small contribution to warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Score tests for association between traits and haplotypes when linkage phase is ambiguous

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Impact of population admixture on the distribution of theCYP3A5*3polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Distribution ofABCB1polymorphisms among Brazilians: impact of population admixture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

The Implications of Population Admixture in Race-based Drug Prescription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

7 January 2021

Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

7 January 2021

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

7 January 2021

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

7 January 2021

Ethnic differences in drug therapy: a pharmacogenomics perspective

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.166

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.166

1 reference

21 December 2017

Dimensions Publication ID

1040035270

0 references

1 reference

21 December 2017